Additional file 1: Figure S1. of ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer

Distribution of ANLN nuclear fraction with regard to tamoxifen treatment. Distribution of ANLN nuclear fraction was analyzed with regard to tamoxifen treatment in cohort II, a randomized prospective tamoxifen trial. The distribution of ANLN nuclear fraction was similar in the treatment and control arms with the majority of tumors expressing less than 25% of ANLN nuclear staining. (PDF 25 kb)